Sign In
Buy AMRX
$12.88
+0.225 (+1.78%)
At Close: Jun 03, 2026
Amneal to Participate at Upcoming Investor Conferences in June
04:05pm, Thursday, 29'th May 2025
BRIDGEWATER, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 5,
3 Reasons Growth Investors Will Love Amneal (AMRX)
01:46pm, Monday, 26'th May 2025
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
US FDA approves Amneal's migraine treatment
08:16am, Thursday, 15'th May 2025
Amneal Pharmaceuticals said on Thursday the U.S. Food and Drug Administration has approved its self-administered migraine drug.
Brekiya® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate pat
Does Amneal (AMRX) Have the Potential to Rally 54.16% as Wall Street Analysts Expect?
11:01am, Friday, 09'th May 2025
The mean of analysts' price targets for Amneal (AMRX) points to a 54.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Here is Why Growth Investors Should Buy Amneal (AMRX) Now
01:45pm, Thursday, 08'th May 2025
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
07:00am, Thursday, 08'th May 2025
-Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation -Expands Amneal's extensive domestic pharmaceu
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call Transcript
11:32am, Friday, 02'nd May 2025
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q1 2025 Earnings Call May 2, 2025 8:30 AM ET Company Participants Tony DiMeo - Head, Investor Relations Chirag Patel - Co-Founder and Co-Chief Executive Off
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:35am, Friday, 02'nd May 2025
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street e
Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates
08:10am, Friday, 02'nd May 2025
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.14 per share a year ago.
Amneal Reports First Quarter 2025 Financial Results
06:00am, Friday, 02'nd May 2025
BRIDGEWATER, N.J.--(BUSINESS WIRE)--AMNEAL REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS.
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
11:06am, Friday, 25'th Apr 2025
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month
08:00am, Friday, 11'th Apr 2025
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month.
BRIDGEWATER, N.J.--(BUSINESS WIRE)--New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® Extended-Release Capsules in Parkinson's Disease.
Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma
08:00am, Tuesday, 01'st Apr 2025
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and Shilpa Medicare Limited (“Shilpa”) toda
